Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Tongxin Dropping Pills versus nicorandil for coronary microvascular dysfunction in patients with anxiety or depression and non-obstructive coronary artery disease
ChiCTR1900025810Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Shexiang Tongxin Dropping Pills and nicorandil in Coronary Small Vessel Disease (CMD), coronary arteriosclerosis, anxiety disorder and 1 more (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Absolute myocardial blood flow, Quantitative myocardial perfusion reserve and 1 more. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
Shexiang Tongxin Dropping Pillsnicorandil
03
Conditions
Coronary Small Vessel Disease (CMD)coronary arteriosclerosisanxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1900025810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025810.